Literature DB >> 18334526

Oral bisphosphonates and atrial fibrillation.

Sumit R Majumdar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18334526      PMCID： PMC2292276          DOI： 10.1136/bmj.39513.481065.80

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  When are observational studies as credible as randomised trials?

Authors:  Jan P Vandenbroucke
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

2.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Authors:  David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan
Journal:  BMJ       Date:  2007-08-02

3.  Alendronate and atrial fibrillation.

Authors:  Steven R Cummings; Ann V Schwartz; Dennis M Black
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

4.  Yearly zoledronic acid in postmenopausal osteoporosis.

Authors:  Roger Karam; John Camm; Michael McClung
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

5.  Relationship between osteoporosis and cardiovascular disease in postmenopausal women.

Authors:  László B Tankó; Claus Christiansen; David A Cox; Mary Jane Geiger; Michelle A McNabb; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2005-07-18       Impact factor: 6.741

6.  Fragility fractures and the osteoporosis care gap: an international phenomenon.

Authors:  L Giangregorio; A Papaioannou; A Cranney; N Zytaruk; J D Adachi
Journal:  Semin Arthritis Rheum       Date:  2006-04       Impact factor: 5.532

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

8.  Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.

Authors:  Henrik Toft Sørensen; Steffen Christensen; Frank Mehnert; Lars Pedersen; Roland D Chapurlat; Steven R Cummings; John A Baron
Journal:  BMJ       Date:  2008-03-11

9.  Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care.

Authors:  Carsten W Israel; Gerian Grönefeld; Joachim R Ehrlich; Yi-Gang Li; Stefan H Hohnloser
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

10.  Zoledronic acid and clinical fractures and mortality after hip fracture.

Authors:  Kenneth W Lyles; Cathleen S Colón-Emeric; Jay S Magaziner; Jonathan D Adachi; Carl F Pieper; Carlos Mautalen; Lars Hyldstrup; Chris Recknor; Lars Nordsletten; Kathy A Moore; Catherine Lavecchia; Jie Zhang; Peter Mesenbrink; Patricia K Hodgson; Ken Abrams; John J Orloff; Zebulun Horowitz; Erik Fink Eriksen; Steven Boonen
Journal:  N Engl J Med       Date:  2007-09-17       Impact factor: 91.245
View more
  3 in total

1.  New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.

Authors:  D Fernández; R Ramis; J Ortega-Castro; R Casasnovas; B Vilanova; J Frau
Journal:  J Comput Aided Mol Des       Date:  2017-06-19       Impact factor: 3.686

2.  Atrial fibrillation and the use of oral bisphosphonates.

Authors:  Michael Pazianas; Cyrus Cooper; Yiting Wang; Jeff L Lange; R Graham G Russell
Journal:  Ther Clin Risk Manag       Date:  2011-03-22       Impact factor: 2.423

3.  Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.

Authors:  Anthony Grosso; Ian Douglas; Aroon Hingorani; Raymond MacAllister; Liam Smeeth
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.